<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MONTELUKAST</span><br/>(mon-te-lu'cast)<br/><span class="topboxtradename">Singulair<br/></span><b>Classifications:</b> <span class="classification">bronchodilator (respiratory smooth muscle relaxant)</span>; <span class="classification">leukotriene receptor antagonist</span><br/><b>Prototype: </b>Zafirlukast<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets; 4 mg chewable tablets; 4 mg oral granules</p>
<h1><a name="action">Actions</a></h1>
<p>Selective receptor antagonist of leukotriene D<sub>4</sub>, thus inhibiting bronchoconstriction. Leukotrienes are considered more important than prostaglandins as inflammatory agents;
         they induce bronchoconstriction and mucus production. Elevated sputum and blood levels of leukotrienes have been documented
         during acute asthma attacks.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Controls asthmatic attacks by inhibiting leukotriene release as well as inflammatory action associated with the attack. Indicated
         by improved pulmonary functions and better controlled asthmatic symptoms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and chronic treatment of asthma or allergic rhinitis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to montelukast; severe asthma attacks; bronchoconstriction due to asthma or NSAIDs; status asthmaticus; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to other leukotriene receptor antagonists (e.g., zafirlukast, zileuton); severe liver disease; severe asthma;
         pregnancy (category B); children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Asthma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg q.d. in evening<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>12 mo5 y</i>, 4 mg q.d. in evening; <i>614 y,</i> 5 mg chewable tablet q.d. in evening<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give in the evening for maximum effectiveness.</li>
<li>Ensure chewable tablets for children are not swallowed whole.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, fever, trauma. <span class="typehead">CNS:</span> Dizziness, <span class="speceff-common">headache</span>. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, gastroenteritis, dental pain, abnormal liver function tests (ALT, AST), diarrhea, nausea. <span class="typehead">Respiratory:</span> Nasal congestion, cough, influenza, laryngitis, pharyngitis, sinusitis. <span class="typehead">Skin:</span> Rash. <span class="typehead">Urogenital:</span> Pyuria. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, bioavailability 64%. <span class="typehead">Peak:</span> 34 h for oral tablet, 22.5 h for chewable tablet. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized by cytochromes P450 3A4 and 2C9. <span class="typehead">Elimination:</span> Excreted in feces. <span class="typehead">Half-Life:</span> 2.75.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor effectiveness carefully when used in combination with phenobarbital or other potent cytochrome P450 enzyme inducers.</li>
<li>Lab test: Periodic liver function tests.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use for reversal of an acute asthmatic attack.</li>
<li>Inform physician if short-acting inhaled bronchodilators are needed more often than usual with montelukast.</li>
<li>Use chewable tablets (contain phenylalanine) with caution with PKU.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>